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1. Introduction  
Pancreatic cancer is one of the most common malignancies of the digestive system and, 
depending on the geographic area, fourth or fifth leading cause of cancer deaths (Lillemoe et 
al, 2000; Simon & Printz, 2001). Between 1960 and 1980, the incidence rates had increased 
significantly in most industrialised countries, including Poland. Corresponding 5-year 
survival rates demonstrated only slight variations and remained stable at about 1-3%. 
Surprisingly, results obtained from some population databases suggest that only about 30% 
of patients registered as pancreatic cancer have been adequately verified by histopathology 
(Wood et al, 2006). Moreover, since many studies included only small groups of patients, 
previous reports did not properly reflect the actual changes, including long-term results of 
treatment (Gudjonsson, 1995). As incidence rates were relatively high and the efficacy of 
therapeutic methods was questionable, pancreatic cancer was subject to numerous clinical 
trials (Jafari & Abbruzzese, 2004). However, no clear conclusions could be drawn in terms of 
the best therapeutic approach due to marked differences between individual studies 
(Gudjonsson, 1995).  
Many epidemiological studies published over the last 50 years provided detailed data for 
some general trends related to incidence and mortality rates for pancreatic cancer. Changes 
in other areas of interest, such as variation in surgical and systemic therapy or long-term 
outcomes are much less examined. Taking into account these facts, an analysis of temporal 
trends for some surgical aspects of pancreatic disorders may provide significant information 
supplementing the results of previous studies.   
2. Methods   
A literature search was performed using two bibliographic databases, i.e. PubMed and 
Ovid. Databases were searched using combinations of the following keywords: (pancreatic 
neoplasm or pancreatic cancer) and (trends or time related changes). Additionally all 
patients diagnosed with pancreatic duct cell cancer (adenocarcinoma ductale) treated between 
1972 and 2003 at the 1st Department of General and GI Surgery of Jagiellonian University 
Medical College in Kraków were reviewed. Other pancreatic tumours verified as non-duct 
cell cancers and periampullary neoplasms were excluded. Clinical and demographic data, 
including age, gender and type of therapeutic interventions, were collected from medical 
records. Tumours were staged according to the TNM classification of Union Internationale 
Contre Le Cancer (UICC) of 1997. The type and extent of surgical treatment was categorised 
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based on commonly accepted criteria (Pedrazzoli et al, 1999). To analyse temporal trends for 
pancreatic cancer, the study interval was divided into three periods, i.e. period 1 (1972-
1983), period 2 (1984-1993) and period 3 (1994-2003).   
3. General epidemiological trends  
Worldwide epidemiological studies on pancreatic cancer have demonstrated slightly higher 
incidence rates in males irrespectively of the geographic area (Katanoda & Dongmei, 2008; 
Katanoda & Yako-Suketomo, 2010; Levi et al, 2003; Michaud, 2004; Sahmoun et al, 2003). 
 Period 1 
1972-1983 
(n=145) 
Period 2 
1984-1993 
(n=294) 
Period 3 
1994-2003 
(n=508) 
P 
Gender female 
 male 
70 (48%) 
75 (52%) 
106 (36%) 
188 (64%) 
222 (44%) 
286 (56%) 
0.027† 
Age, median (95%CI) 58 (57-62) 60 (58-62) 63 (62-65) <0.001‡ 
Location head 
 body 
 tail 
89 (61%) 
50 (35%) 
6 (4%) 
199 (68%) 
71 (24%) 
24 (8%) 
341 (67%) 
140 (28%) 
27 (5%) 
0.147† 
Stage  I 
 II 
 III 
 IV 
0 (0%) 
3 (2%) 
8 (6%) 
134 (92%) 
7 (2%) 
2 (1%) 
11 (4%) 
274 (93%) 
5 (1%) 
16 (3%) 
32 (6%) 
455 (90%) 
0.047† 
Therapy surgical 
 conservative 
117 (81%) 
28 (19%) 
228 (78%) 
66 (22%) 
376 (74%) 
132 (26%) 
0.192† 
Type of surgical procedures 
 resective 
 non-resective 
 
11 (9%) 
106 (91%) 
 
46 (20%) 
182 (80%) 
 
115 (31%) 
261 (69%) 
<0.001† 
Type of pancreatic resections 
 PD 
 PPD 
 distal pancreatectomy 
 total pancreatectomy 
 
8 (73%) 
0 (0%) 
2 (18%) 
1 (9%) 
 
22 (48%) 
4 (8%) 
10 (22%) 
10 (22%) 
 
46 (40%) 
14 (12%) 
22 (19%) 
33 (29%) 
0.557† 
Type of non-resective surgery 
 laparotomy 
 biliary bypass 
 gastro-enteric bypass 
 biliary and enteric bypass 
 
38 (36%) 
55 (52%) 
4 (4%) 
9 (8%) 
 
62 (34%) 
64 (35%) 
13 (7%) 
43 (24%) 
 
81 (31%) 
19 (7%) 
67 (26%) 
94 (36%) 
<0.001† 
Chemotherapy 
 no 
 yes 
 
138 (95%) 
7 (5%) 
 
222 (76%) 
72 (24%) 
 
231 (45%) 
277 (55%) 
<0.01† 
Median survival, months (95%CI) 
 overall 
 pancreatic resections 
 unresectable tumours 
 
5.2 (4.7-5.6) 
26.6 (10.4-42.8) 
5.0 (4.5-5.6) 
 
6.2 (5.2-7.2) 
14.3 (11.2-17.4) 
5.5 (4.6-6.5) 
 
7.6 (6.7-8.5) 
20.0 (13.7-26.3) 
5.9 (5.1-6.6) 
 
<0.001§ 
0.041§ 
<0.001§ 
Table 1. Demographic and clinical data of patients with pancreatic cancer 
(PD –pancreatoduodenectomy, PPPD – pylorus-preserving PD, † chi-square test;  
‡ ANOVA analysis of variance, § log-rank test)  
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Most authors agree that this phenomenon is mainly related to the exposure to carcinogens, 
particularly smoking. The role of the latter factor has been confirmed by increasing 
incidence trends in populations with a high proportion of smoking individuals and 
lowering incidence in countries where smoking is decreasing, i.e. Sweden (Bobak, 2003; 
Flook & van Zanten, 2009; Luo et al, 2008; Mulder et al, 2002; Simon & Printz, 2001).  
Between 1972 and 2003, a total of 1708 patients with chronic pancreatic and periampullary 
disorders were hospitalised, including 947 patients with histopathologically verified 
pancreatic duct cell cancer (Popiela et al, 2007). Fifty-eight per cent of 947 patients with 
pancreatic cancer were males (n=549) and 42% (n=398) females. Although the proportion of 
males increased temporarily to 64% in period 2, it subsequently decreased to values 
observed in period 1 (tab. 1). The median age was 62 years (95% confidence interval [CI] 61 – 
62) and demonstrated a significant increasing trend over time. Similarly to other authors, we 
have recorded a significant increase in the proportion of females diagnosed with pancreatic 
cancer over the last twenty years. The significant increasing trend for the median age shown 
in our series was similar to other reports where growing numbers of pancreatic resections 
were carried out in elderly patients (Delcore et al, 1991; DiCarlo et al, 1998; Sohn et al, 1998).  
4. Changes in pathological findings  
Numerous changes have been observed worldwide in the diagnostics of pancreatic cancer 
during the last five decades. The number of cases diagnosed at laparotomy carried out due 
to jaundice or epigastric complaints decreased sharply as abdominal ultrasound was 
introduced into routine clinical practice (Soreide et al, 2010). Subsequently, ultrasound was 
gradually replaced by less operator-dependent imaging techniques, such as computed 
tomography (CT) and magnetic resonance imaging (MRI). A gradual increase in the use of 
endoscopic ultrasonography (EUS) and positron emission tomography (PET) has been 
observed over the recent years, but their application is usually limited to some specific 
clinical situations. The proportion of patients diagnosed solely with US and CT nowadays 
varies between 75% and 85%, while other imaging techniques (MRI, PET, EUS) are used less 
frequently (David et al, 2009; Ngamruengphong et al, 2010). 
The majority of lesions treated in our centre was located in the head of the pancreas (n=629, 
66%), whereas cancers of the body and tail were found in 28% (n=261) and 6% (n=57) of 
cases, respectively. There were no significant differences in the proportions of tumours 
located in the head, body and tail of the pancreas over time (Popiela et al, 2007). However, 
other authors suggested some variation over time. Based on 43,946 cases of pancreatic 
cancer recorded between 1973 and 2002 in the Surveillance, Epidemiology, and End Results 
(SEER), Lau et al. found a 46% increase in the incidence of body/tail cancers (Lau et al, 
2010). Reports from other geographic areas mostly failed to demonstrate any significant 
change in the prevalence of distally-located cancers. 
Technical improvements in imaging methods and their wider accessibility should theoretically 
allow for an earlier diagnosis of pancreatic cancer leading to reduced proportions of advanced 
tumours and increased resectability rates. Surprisingly, most cohort studies failed to 
demonstrate any marked increase in the proportion of cancers at a lower stage (Cress et al, 
2006; Janes et al, 1996; Niederhuber et al, 1995; Riall et al, 2006; Sener et al, 1999). The percentage 
of patients with stage IV tumours in our series, similarly to other reports, showed only a slight 
lowering trend. Although this phenomenon was accompanied by increasing resectability rates, 
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the proportion of stage groups in patients undergoing pancreatic resections remained stable. 
Similarly to our findings, other authors reported only slight variations in staging patients with 
pancreatic cancer. In a population of 2986 cases of pancreatic cancer from the Digestive Cancer 
Registry of Burgundy (France) over a 30-year period (1976–2005) the overall proportion of 
stage I, II and III tumours was 1.3%, 2.2% and 5.4%, respectively (David et al, 2009). The 
proportion of stage I–II cancers slightly increased from 2.8% in the 1976–1980 period to 8.8% in 
the 2001–2005 period, though these changes were highly significant (P<0.001). Nevertheless, 
metastatic and/or non-resected cases decreased only by about 10% from 95.2% to 85.5%. The 
increasing trend of resectability rates found in this study was also confirmed by authors from 
various geographic areas. In a group of 16,758 patients treated between 1980 and 2000 in 
Sweden, the proportion of resectable tumours observed by Linder et al. increased from 7.2% to 
15.1% (Linder et al, 2006). A similar trend was reported for the US population in a recent study 
involving 24,016 patients (Riall et al, 2006).  
5. Surgical trends  
Improved diagnostic methods increased the percentage of patients diagnosed with metastatic 
disease before surgery. Simultaneous development of endoscopic methods allows to perform 
biliary or duodenal stenting, and along with better imaging tests, has contributed to the 
decreasing rates of open surgery in patients with disseminated disease (Lefebvre et al, 2009).  
Two hundred and twenty-six of 947 analysed patients (24%) were disqualified from surgical 
intervention. The remaining 721 (76%) patients were subject to surgical therapy and this 
proportion decreased insignificantly from 81% to 74% in the last decade. Pancreatic resections 
were performed in 172 (24%) patients and the resectability rate increased significantly from 9% 
to 31% between period 1 and 3, respectively. No significant changes in the type of pancreatic 
resections could be demonstrated for the whole cohort. However, an increasing proportion of 
pylorus-preserving pancreaticoduodenectomy (Traverso procedure) from 0% to 23% in the last 
period was found for lesions located in the head of the pancreas. The percentage of patients 
undergoing only exploratory laparotomy was stable over time with a mean value of 33%. The 
proportion of patients with biliary bypass significantly decreased with a concomitant increase 
in the ratio of gastro-enteric and double bypass procedures. 
A gradual increase in endoscopic procedures is commonly reported in most reports. Linder et 
al. reported a significant reduction in the proportion of patient subject to surgical biliary 
bypass from 45.9% between 1980 and 1986 to 18.1% between 1994 and 2000 (Linder et al, 2006). 
These changes were accompanied by a lowering percentage of gastro-enteric bypass from 
33.8% to 22.8%. Lefebvre et al. reported a similar decreasing trend for palliative surgery from 
55% in 1978–1982 to 32% in 1998–2002 due to the more common use of endoscopic stenting 
(Lefebvre et al, 2009). We have found analogical variations in biliary bypass from 52% to 7%, 
but as opposed to Linder et al. the percentage of gastro-enteric and simultaneous biliary and 
enteric bypasses increased from 4% to 26% and from 8% to 36%, respectively. This change in 
the therapeutic strategy was related mainly to our analysis of patients requiring open surgery 
for upper gastrointestinal ileus and results of randomized clinical trials supporting the idea of 
prophylactic gastro-enteric bypass (Lillemoe et al, 1999; Popiela et al, 2002b; Van Heek et al, 
2003). The increasing proportion of pylorus-preserving pancreaticoduodenectomy observed in 
the last decade for patients undergoing pancreatic head resections reflects the current belief 
that the procedure does not impair oncological radicality and, as suggest some authors, 
reduces adverse metabolic consequences of pancreatic resections (Schafer et al, 2002). 
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The most important aspect of surgery-related trends in pancreatic cancer is associated with 
markedly decreasing postoperative mortality. We have observed similar changes in the 
early postoperative outcomes and long-term survival as those reported by other authors 
(Popiela et al, 2002b; Sierzega et al, 2006). In particular, a significant lowering trend of 
postoperative mortality rates was found from values exceeding 10% in the early eighties to 
an average of 4.1% in the last decade (fig. 1) (Popiela, 1979; Popiela et al, 2004).   
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Fig. 1. Postoperative mortality rates for pancreatic resections in consecutive years  
6. Trends in systemic therapy  
Pancreatic surgery has reached a plateau in terms of long-term survival observed for 
patients with pancreatic cancer (Popiela et al, 2002a; Popiela et al, 2002c). Therefore, further 
improvements should only be expected from combined modality therapy. IN our series, 
various regimens of chemotherapy were used in 38% (n=356) of cases and the percentage of 
patients qualified of systemic therapy increased significantly from 5% in period 1 to 55% in 
period 3. Fluorouracil was the primary chemotherapeutic agent until 1997 and afterwards 
was replaced by multidrug regimens based on gemcitabine, cisplatin and irinotecan.  
Although there is no uniform consensus on adjuvant therapy of pancreatic cancer, a recent 
meta-analysis of clinical trials have supported the benefits of chemotherapy found in our 
study (Stocken et al, 2005). The most recent analysis of data from the SEER registry in 1910 
patients who underwent resections for pancreatic adenocarcinoma performed between 1991 
and 2002 reflects the overall change in the proportion of patients qualified for systemic 
treatment after surgical intervention (Simons et al, 2010). The proportion of subjects 
receiving adjuvant chemoradiotherapy in US increased from 26% in 1991–1993 to 37% in 
2000-2002. The role of palliative chemotherapy is also increasing as demonstrated in a recent 
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meta-analysis of clinical trials, where chemotherapy significantly prolonged survival 
compared to symptomatic therapy (Yip et al, 2009). Another meta-analysis on gemcitabine 
combined with platinum agents provided additional proofs for combination therapy, as the 
concomitant use of both drugs significantly increased response rates and prolonged time to 
progression (Xie et al, 2006). Results of our studies showed that any gemcitabine based 
regimen of palliative chemotherapy produced better results than observed in control groups 
and the combination of gemcitabine and cisplatin was the most effective regimen (Popiela et 
al, 2001; Popiela et al, 2005). Increased rates of adjuvant and palliative chemotherapy have 
been reported by several authors (David et al, 2009; Lefebvre et al, 2009).   
7. Changes in prognosis  
The overall median survival in our series was 7.1 months (95%CI 6.6 to 7.6) and was 
significantly longer after pancreatic resections (median 14.8 months; 95%CI 11.5 to 16.9) than 
in the remaining cases (median 5.8 months; 95%CI 4.4 to 6.9). The overall 5-year survival 
rate was 4.5% and increased to 14.3% for resective cases. No patient with unresectable 
tumour survived 5 years from the time of diagnosis. Pairwise comparisons of survival 
functions demonstrated statistically significant differences between each stage according to 
UICC 1997 (fig. 2).  
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Fig. 2. Stage-specific survival for resectable pancreatic cancer  
The 5-year survival rate for stage I was 50.3% with a median survival of 63.1 months (95%CI 
7.6 to 118.6). Five-year survival rates of 16.5% and 5.9% for stage II and III, respectively, 
were significantly lower. Corresponding median survival times were 33.2 months (95%CI 
21.0 to 45.5) and 20.1 months (95%CI 14.8 to 25.3). The median survival of patients with 
stage IV cancers was 6.2 months (95%CI 5.7-6.6) and no patient survived 5 years. The 
median and 5-year survival rates after curative resections (R0 according to UICC) were 27.9 
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months and 29.4%, respectively. The corresponding duration of median survival for 
microscopically (R1) and macroscopically (R2) non-radical resections of 11.4 and 11 months 
was significantly shorter. No patient survived 5 years after either R1 or R2 resection. A 
significant increasing trend for overall survival was found between period 1 and 3 (fig. 3, 
tab. 1). The correlation coefficient for the median survival of patients treated in consecutive 
years was 0.59 and this increasing trend was statistically significant (fig. 4). The median 
survival of patients undergoing pancreatic resections during the last decade (20 months, 
95%CI 13.7 to 26.3) was significantly longer than for the period 1984-1993 (14.3 months, 
95%CI 11.2 to 17.4). However, the differences between median survival during 1972-1983 
and 1984-1993 or 1972-1983 and 1994-2003 were statistically insignificant (fig. 5). 
Nevertheless, the median survival of patients with unresectable tumours increased 
significantly between consecutive periods (fig. 6).  
Long-term results in patients treated for pancreatic cancer demonstrate only slight 
variations over the last 30 years with 5-year survival rates of 1-3% (Gudjonsson, 1995; 
Lillemoe et al, 2000; Tsiotos et al, 1999). Nevertheless, the number of reports describing 
improving survival trends is growing (Riall et al, 2006; Wood et al, 2006). The 2.4-month 
increase in the overall median survival found in our patients was due to improvements 
observed in both resectable (from 14.3 months between 1984 and 1993 to 20 months between 
1994 and 2003), and unresectable cases (from 5 months between 1972 and 1983 to 5.9 months 
in the last decade). The relatively high median survival (26.6 months) in resectable patients 
treated in period 1 was related to the small number of cases (11 patients). In a recent 
publication of 1423 patients undergoing pancreaticoduodenectomy for pancreatic cancer, 
the median survival increased significantly from 8 months in the eighties to 19 months in 
patients operated after 2000 with comparable proportions of stage groups (Winter et al, 2006). 
A similar trend was also reported by Riall et al. in a large study on unresectable 
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Fig. 3. Overall survival functions for individual time periods  
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Fig. 4. Changes in median survival in consecutive years  
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Fig. 5. Changes in survival in consecutive years for resectable tumours  
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Fig. 6. Changes in median survival in consecutive years for unresectable tumours  
pancreatic cancer (Riall et al, 2006). In 12043 cases of disseminated disease, the proportion of 
patients who survived 2 years increased from 1.4% between 1988 and 1991 to 2.3% between 
1996 and 1999. A recent analysis of the SEER database showed a similar improving trend for 
overall survival in patients with pancreatic cancer (Lau et al, 2010). The overall 3-year 
survival rate increased from 4.3% to 6.2% from 1973 to 1987 to 1988 to 2002 for tumours of 
the pancreatic head and from 2.8% to 3.9% in pancreatic body/tail cancers. Similar 
observations were reported from the South Australian Cancer Registry covering the period 
from 1977 to 2006 with 4,166 pancreatic cancers (Luke et al, 2009) and 21,663 patients from 
the Cancer Registry of Norway for the period 1965–2007 (Soreide et al, 2010).  
8. Conclusion  
The analysis of 947 patients with pancreatic cancer treated between 1972 and 2003 
demonstrated the existence of significant trends mainly for early postoperative and long-term 
outcomes. Postoperative mortality rates significantly decreased from values exceeding 10% in 
the early eighties to an average of 4.1% in the last decade. The overall median survival 
increased from 5.2 to 7.6 months and this change was reflected by improving outcomes in both 
resectable and unresectable disease. The observed changes are attributed mainly to the 
increasing role of combined therapy and emphasise the importance of such an approach.  
Even with easily accessible imaging tests, the majority of patients with either cancer is still 
diagnosed at an advanced stage. Therefore, improved diagnostic procedures at the level of pre-
hospital care are the key for actual improvement of patients’ survival. Primary care physicians 
and specialists diagnosing patients with obstructive jaundice are of particular importance since 
endoscopic procedures commonly performed by gastroenterologists cannot be regarded as 
curative therapy and the need for surgical exploration should always be considered. 
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